EUVIMEDEUVIMED entdecken
Kohortenstudie

Real-world evidence of lisinopril in pediatric hypertension and nephroprotective management: a 10-year cohort study

Eva Degraeuwe, Elke Gasthuys, Evelien Snauwaert, Lien Dossche, Agnieszka Prytula, Joke Dehoorne, An Vermeulen, Johan Vande Walle, Ann Raes

Pediatric Nephrology · 2025-03 · 40 (3) · 797-809

DOI: 10.1007/s00467-024-06531-1 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pediatric Nephrology, online erschienen am 28.10.2024. Verfasst von Eva Degraeuwe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Diseases and Pediatrics, Faculty of Health and Medical Sciences, Ghent University, Ghent, Belgium. eva.degraeuwe@ugent.be. Hauptthemen laut MEDLINE: Lisinopril, Hypertension, Antihypertensive Agents, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Over the last 20 years, pediatric hypertension (pHTN) prevalence in Western society has risen from 3.5 to 9% due to childhood overweight, obesity, and secondary kidney and cardiological conditions. Few studies have assessed commonly used antihypertensive medication lisinopril's (ACE-inhibitor) long-term efficacy and the long-term value of renin-angiotensin-aldosterone system (RAAS) biomarkers. METHODS: This is a retrospective cohort study at Ghent University Hospital, Belgium, with 106 young patients (1-18 years) treated with lisinopril due to hypertension (HTN) and chronic kidney disease (CKD) assessed for treatment outcomes against clinical benchmarks over 10 years. RESULTS: Lisinopril was mainly initiated for secondary hypertension or nephroprotection (89%) due to kidney causes. A starting dose across groups was lower than 0.07 mg/kg for 48% (n = 50). HTN patients without CKD achieved systolic blood pressure below the 95th percentile within 2 years, but efficacy declined after 2.5 years. CKD patients maintained a steady response, reaching systolic targets by 40 months and showing improved diastolic control over 70 months. Proteinuria reduction had a median urine protein creatinine ratio (UPCR) to 0.57 g/g at 6 months, with a reappearance of UPCR 2 g/g creatinine after 40 months. Aldosterone breakthrough occurred from 6 months onward in all groups. Over 70 months, aldosterone and aldosterone-renin-ratio (ARR) progression significantly differ between children with and without normal kidney function. CONCLUSIONS: Treatment efficacy for systolic blood pressure in hypertensive patients with abnormal kidney function diminishes after 2.5 years and for proteinuria in children after 3 years, highlighting the need for dosage recalibration according to guidelines and/or the need for alternative treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LisinoprilHypertensionAntihypertensive AgentsRenal Insufficiency, ChronicAngiotensin-Converting Enzyme InhibitorsHumansChildAdolescentMaleRetrospective StudiesFemaleChild, PreschoolInfantTreatment OutcomeRenin-Angiotensin SystemBlood PressureBelgiumProteinuria

Stichwörter der Autor:innen

ACE-inhibitorHypertensionLisinoprilPediatrics

Substanzen

LisinoprilAntihypertensive AgentsAngiotensin-Converting Enzyme Inhibitors

Autor:innen und Institutionen

  • Department of Internal Diseases and Pediatrics, Faculty of Health and Medical Sciences, Ghent University, Ghent, Belgium. eva.degraeuwe@ugent.be.
  • Ghent University Hospital (UZ Gent), ERKNET Center, ERN Transplantchild, Ghent, Belgium. eva.degraeuwe@ugent.be.
  • Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
  • Department of Internal Diseases and Pediatrics, Faculty of Health and Medical Sciences, Ghent University, Ghent, Belgium.
  • Ghent University Hospital (UZ Gent), ERKNET Center, ERN Transplantchild, Ghent, Belgium.

Zitieren

APA

Degraeuwe, E., Gasthuys, E., Snauwaert, E., Dossche, L., Prytula, A., Dehoorne, J., Vermeulen, A., Walle, J. V., & Raes, A. (2025). Real-world evidence of lisinopril in pediatric hypertension and nephroprotective management: a 10-year cohort study. Pediatric Nephrology, 40(3), 797-809. https://doi.org/10.1007/s00467-024-06531-1

Vancouver

Degraeuwe E, Gasthuys E, Snauwaert E, Dossche L, Prytula A, Dehoorne J, et al. Real-world evidence of lisinopril in pediatric hypertension and nephroprotective management: a 10-year cohort study. Pediatric Nephrology. 2025;40(3):797-809. doi:10.1007/s00467-024-06531-1

BibTeX
@article{Degraeuwe2025,
  author = {Degraeuwe, Eva and Gasthuys, Elke and Snauwaert, Evelien and Dossche, Lien and Prytula, Agnieszka and Dehoorne, Joke and Vermeulen, An and Walle, Johan Vande and Raes, Ann},
  title = {Real-world evidence of lisinopril in pediatric hypertension and nephroprotective management: a 10-year cohort study},
  journal = {Pediatric Nephrology},
  year = {2025},
  volume = {40},
  number = {3},
  pages = {797--809},
  doi = {10.1007/s00467-024-06531-1}
}
Kostenlos starten →